Welcome to our dedicated page for Tivic Health Systems news (Ticker: $TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tivic Health Systems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tivic Health Systems's position in the market.
Tivic Health announced its Q1 2024 financial results and subsequent events, marking significant progress in the bioelectronics field. The company reported a gross profit increase of 48% and a reduction in operating loss by nearly 30% year-over-year. Net loss decreased to $1.5 million from $2.1 million in Q1 2023. Despite an 11% drop in revenue to $334 thousand, gross margin improved to 50% from 30%.
Significant milestones included the completion of patient enrollment in a vagus nerve stimulation study and the launch of ClearUP 2.0. A recent public offering raised $4 million, boosting cash reserves to $4.7 million as of May 14, 2024.
Key developments also included a major distribution agreement and positive clinical trial results demonstrating the efficacy of their non-invasive vagus nerve stimulation technology. The company continues to invest in its intellectual property portfolio.
Tivic Health, trading under the ticker TIVC, will announce its Q1 2024 financial results on May 15th via a pre-recorded conference call and webcast. The call is scheduled for 1:30 PM PT / 4:30 PM ET. The company specializes in developing and commercializing bioelectronic medicine. Stakeholders can join the call using the provided toll-free and international numbers, or view the webcast online.
Tivic Health Systems announced the closing of a $4.0 million public offering. The offering included 4,710,000 shares of common stock, Series A warrants for 4,710,000 shares, and Series B warrants for 7,065,000 shares, all priced at $0.85 per share. The Series A warrants are exercisable immediately and expire in one year, while the Series B warrants also exercisable immediately, expire in five years. Maxim Group served as the sole placement agent. The gross proceeds before fees and expenses amounted to $4.0 million. The offering was made through a registration statement declared effective by the SEC on May 9, 2024. Investors can access the final prospectus on the SEC website.
Tivic Health Systems, a health tech company, announced the pricing of a public offering consisting of common stock and warrants, expecting to raise approximately $4.0 million. The offering includes Series A and Series B warrants with different terms and exercise prices. The closing is scheduled for May 13, 2024, subject to customary conditions. Maxim Group is the sole placement agent for the offering.
Tivic Health announced successful completion of a pilot research study showing the effectiveness of their non-invasive vagus nerve stimulation approach in inducing responses in the autonomic, cardiac, and central nervous systems. Results included a 97% increase in heart rate variability and changes in brain activity consistent with reduced arousal and anxiety. The company aims to improve bioelectronic medicine and expand into new market segments. VNS is a growing market with significant potential in various medical conditions.